Advertisement

Journal of Inherited Metabolic Disease

, Volume 35, Issue 6, pp 963–973 | Cite as

An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia

  • Thomas Opladen
  • Georg F. Hoffmann
  • Nenad Blau
Original Article

Abstract

Objectives

The present study summarizes clinical and biochemical findings, current treatment strategies and follow-up in patients with tetrahydrobiopterin (BH4) deficiencies.

Methods

We analyzed the clinical, biochemical and treatment data of 626 patients with BH4 deficiencies [355 with 6-pyruvoyl-tetrahydropterin synthase (PTPS), 217 with dihydropteridine reductase (DHPR), 31 with autosomal recessive GTP cyclohydrolase I (GTPCH), and 23 with pterin-4a-carbinolamine dehydratase (PCD) deficiencies] from the BIODEF Database. Patients with autosomal dominant GTPCH and SR deficiencies will not be discussed in detail.

Results

Up to 57 % of neonates with BH4 deficiencies are already clinically symptomatic. During infancy and childhood, the predominant symptoms are muscular hypotonia, mental retardation and age-dependent movement disorders, including dystonia. The laboratory diagnosis of BH4 deficiency is based on a positive newborn screening (NBS) for phenylketonuria (PKU), characteristic profiles of urinary or dried blood spot pterins (biopterin, neopterin, and primapterin), and the measurement of DHPR activity in blood. Some patients with autosomal recessive GTPCH deficiency and all with sepiapterin reductase deficiency may be diagnosed late due to normal blood phenylalanine in NBS. L-dopa, 5-hydroxytryptophan, and BH4 are supplemented in PTPS and GTPCH-deficient patients, whereas L-dopa, 5-hydroxytryptophan, folinic acid and diet are used in DHPR-deficient patients. Medication doses vary widely among patients, and our understanding of the effects of dopamine agonists and monoamine catabolism inhibitors are limited.

Conclusions

BH4 deficiencies are a group of treatable pediatric neurotransmitter disorders that are characterized by motor dysfunction, mental retardation, impaired muscle tone, movement disorders and epileptic seizures. Although the outcomes of BH4 deficiencies are highly variable, early diagnosis and treatment result in improved outcomes.

Keywords

Dystonia Biogenic Amine Folinic Acid Neopterin Pterin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We would like to thank all contributing medical centers and their physicians for providing biochemical, clinical, and follow-up date to the BIODEF database. This work was supported by the Swiss National Science Foundation grant no. 31003A-119982, by the BIOPKU, Switzerland, and by the “Forschungsförderung” of the German Metabolic Society (APS).

Conflict of interest

None.

References

  1. al Aqeel A, Ozand PT, Gascon G et al (1991) Biopterin-dependent hyperphenylalaninemia due to deficiency of 6-pyruvoyl tetrahydropterin synthase. Neurology 41:730–737PubMedCrossRefGoogle Scholar
  2. Blau N, Burgard P (2006) Disorders of Phenylalanine and Tetrahydrobiopterin Metabolism. In: Blau N, Hoffmann GF, Leonard J, Clarke JTR (eds) Physician’s Guide to the Treatment and Follow-up of Metabolic Diseases. Springer, Berlin, pp 25–34CrossRefGoogle Scholar
  3. Blau N, Barnes I, Dhondt JL (1996) International database of tetrahydrobiopterin deficiencies. J Inherit Metab Dis 19:8–14PubMedCrossRefGoogle Scholar
  4. Blau N, Thöny B, Cotton RGH, Hyland K (2001) Disorders of tetrahydrobiopterin and related biogenic amines. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B (eds) The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York, pp 1725–1776Google Scholar
  5. Blau N, Duran M, Blaskovics M, Gibson KM (2003) Disorders of phenylalanine and tetrahydrobiopterin metabolism. In: Blau N, Bonafe L, Blaskovics M (eds) Physician's Guide to Laboratory Diagnosis of Metabolic Diseases. Springer, Berlin, pp 89–106CrossRefGoogle Scholar
  6. Blau N, Duran M, Gibson KM (2008) Laboratory guide to the methods in biochemical genetics. Springer, BerlinCrossRefGoogle Scholar
  7. Blau N, van Spronsen FJ, Levy HL (2010) Phenylketonuria. Lancet 376:1417–1427PubMedCrossRefGoogle Scholar
  8. Bonafe L, Thöny B, Leimbacher W, Kierat L, Blau N (2001) Diagnosis of dopa-responsive dystonia and other tetrahydrobiopterin disorders by the study of biopterin metabolism in fibroblasts. Clin Chem 47:477–485PubMedGoogle Scholar
  9. Bonafé L, Thöny B, Penzien JM, Czarnecki B, Blau N (2001) Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine neurotransmitter deficiency without hyperphenylalaninemia. Am J Hum Genet 69:269–277PubMedCrossRefGoogle Scholar
  10. Concolino D, Muzzi G, Rapsomaniki M, Moricca MT, Pascale MG, Strisciuglio P (2008) Serum prolactin as a tool for the follow-up of treated DHPR-deficient patients. J Inherit Metab Dis Dec 31:S193–S197CrossRefGoogle Scholar
  11. Crabtree MJ, Tatham AL, Al-Wakeel Y et al (2009) Quantitative regulation of intracellular endothelial nitric-oxide synthase (eNOS) coupling by both tetrahydrobiopterin-eNOS stoichiometry and biopterin redox status: insights from cells with tet-regulated GTP cyclohydrolase I expression. J Biol Chem 284:1136–1144PubMedCrossRefGoogle Scholar
  12. Friedman J, Roze E, Abdenur JE et al (2012) Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 71:520–530.Google Scholar
  13. Fukushima T, Nixon JC (1980) Analysis of reduced forms of biopterin in biological tissues and fluids. Anal Biochem 102:176–188PubMedCrossRefGoogle Scholar
  14. Gasnier B (2000) The loading of neurotransmitters into synaptic vesicles. Biochimie 82:327–337PubMedCrossRefGoogle Scholar
  15. Herlenius E, Lagercrantz H (2001) Neurotransmitters and neuromodulators during early human development. Early Hum Dev 65:21–37PubMedCrossRefGoogle Scholar
  16. Irons M, Levy HL, O'Flynn ME et al (1987) Folinic acid therapy in treatment of dihydropteridine reductase deficiency. J Pediatr 110:61–67PubMedCrossRefGoogle Scholar
  17. Jäggi L, Zurfluh MR, Schuler A et al (2008) Outcome and long-term follow-up of 36 patients with tetrahydrobiopterin deficiency. Mol Genet Metab 93:295–305PubMedCrossRefGoogle Scholar
  18. Longo N (2009) Disorders of biopterin metabolism. J Inherit Metab Dis 32:333–342PubMedCrossRefGoogle Scholar
  19. Niu DM (2011) Disorders of BH4 metabolism and the treatment of patients with 6-pyruvoyl-tetrahydropterin synthase deficiency in Taiwan. Brain Dev 33:847–855PubMedCrossRefGoogle Scholar
  20. Opladen T, Abu Seda B, Rassi A, Thöny B, Hoffmann GF, Blau N (2011a) Diagnosis of tetrahydrobiopterin deficiency using filter paper blood spots: further development of the method and 5 years experience. J Inherit Metab Dis Jun 34:819–826CrossRefGoogle Scholar
  21. Opladen T, Hoffmann G, Hörster F et al (2011b) Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. Mov Disord 26:157–161PubMedCrossRefGoogle Scholar
  22. Ponzone A, Blau N, Guardamagna O, Ferrero GB, Dianzani I, Endres W (1990) Progression of 6-pyruvoyl-tetrahydropterin synthase deficiency from a peripheral into a central phenotype. J Inherit Metab Dis 13:298–300PubMedCrossRefGoogle Scholar
  23. Ponzone A, Guardamagna O, Ferraris S, Ferrero GB, Dianzani I, Cotton RGH (1991) Tetrahydrobiopterin loading test in hyperphenylalaninemia. Pediatr Res 30:435–438PubMedCrossRefGoogle Scholar
  24. Ponzone A, Spada M, Ferraris S, Dianzani I, De Sanctis L (2004) Dihydropteridine reductase deficiency in man: from biology to treatment. Med Res Rev 24:127–150PubMedCrossRefGoogle Scholar
  25. Porta F, Mussa A, Concolino D, Spada M, Ponzone A (2009) Dopamine agonists in 6-pyruvoyl tetrahydropterin synthase deficiency. Neurology 73:633–637PubMedCrossRefGoogle Scholar
  26. Smith I, Clayton BE, Wolff OH (1975) New variant of phenylketonuria with progressive neurological illness unresponsive to phenylalanine restriction. Lancet 1:1108–1111PubMedCrossRefGoogle Scholar
  27. Smith I, Hyland K, Kendall B (1985) Clinical role of pteridine therapy in tetrahydrobiopterin deficiency. J Inherit Metab Dis 8:39–45PubMedCrossRefGoogle Scholar
  28. Thöny B, Blau N (2006) Mutations in the BH4-metabolizing genes GTP cyclohydroalse I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase genes. Hum Mutat 27:870–878PubMedCrossRefGoogle Scholar
  29. Wang L, Yu WM, He C et al (2006) Long-term outcome and neuroradiological findings of 31 patients with 6-pyruvoyltetrahydropterin synthase deficiency. J Inherit Metab Dis 29:127–134PubMedCrossRefGoogle Scholar
  30. Werner ER, Blau N, Thöny B (2011) Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J 438:397–414PubMedGoogle Scholar
  31. Woody R, Brewster M, Glasier C (1989) Progressive intracranial calcification in dihydropteridine reductase deficiency prior to folinic acid therapy. Neurology 39:673–675PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer 2012

Authors and Affiliations

  • Thomas Opladen
    • 1
  • Georg F. Hoffmann
    • 1
  • Nenad Blau
    • 1
    • 2
  1. 1.Division of Inborn Metabolic DiseasesUniversity Childrens Hospital HeidelbergHeidelbergGermany
  2. 2.University Children’s Hospital ZürichZurichSwitzerland

Personalised recommendations